Effect of CRF injected into the median eminence on GH secretion in female rats under different steroid status.
To evaluate whether the median eminence (ME) is a site of action of CRF (corticotropin releasing factor) on GH secretion and to determine the possible role of estradiol and progesterone in modifying theses secretion, we injected CRF (0.25, 0.75, 1, and 1.5 nmol of peptide dissolved in 1 microliter of water) directly into the ME in three experimental groups of rats: Long-term ovariectomized (OVX); OVX primed by estradiol (OVX +/- E) and OVX primed by estradiol plus progesterone (OVX +/- EP). Blood was collected to determine GH (30, 60, 90, and 120 min postinjection). Serum T3, T4, and glucose levels were measured in OVX +/- E rats 30 min postinjection. CRF at all doses studied significantly decreased serum GH levels in the three experimental groups. Serum T3, T4, and glucose levels were unchanged after CRF administration. The results suggest that: CRF inhibits "per se" GH secretion, at least in part, by a central action in the ME. The inhibitory effect of CRF on GH is independent of the estrogen/progesterone status of the animal. CRF at ME levels may participate in a variety of stress-related responses, including growth inhibition, through GH suppression.
Puertas
A
A
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Granada, Spain.
Frias
J
J
Ruiz
E
E
Ortega
E
E
D000818:Animals; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D007700:Kinetics; D008473:Median Eminence / Q000187:drug effects / Q000502:physiology*; D008845:Microinjections; D010052:Ovariectomy; D011374:Progesterone / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D011374:Progesterone; D004958:Estradiol; D013006:Growth Hormone; D003346:Corticotropin-Releasing Hormone